| Identification | Back Directory | [Name]
Utibapril | [CAS]
109683-61-6 | [Synonyms]
FPL-63547
Utibapril
(2S)-5-tert-Butyl-3-[(2S)-2-[[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino]propanoyl]-2,3-dihydro-1,3,4-thiadiazole-2β-carboxylic acid
1,3,4-Thiadiazole-2-carboxylic acid, 5-(1,1-dimethylethyl)-3-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-2,3-dihydro-, (2S)- | [Molecular Formula]
C22H31N3O5S | [MDL Number]
MFCD00865862 | [MOL File]
109683-61-6.mol | [Molecular Weight]
449.56 |
| Hazard Information | Back Directory | [Uses]
Utibapril is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activities. | [in vivo]
Utibapril significantly inhibits plasma, renal, and vascular ACE but not ventricular ACE activity. Utibapril (2 μg/kg/day) significantly inhibits vascular ACE activity, and Utibapril (250 μg/kg/day) results in a significant inhibition of plasma ACE. Furthermore, angiotensin I-induced decreases in coronary flow in the isolated heart are significantly inhibited after treatment with the higher doses of utibapril[1]. FPL 63547 is rapidly and extensively excreted as the diacid in the bile but appeared in the urine in negligible amounts[2]. | [storage]
Store at -20°C | [References]
[1] Buikema H, et al. Differential inhibition of plasma versus tissue ACE by utibapril: biochemical and functional evidence for inhibition of vascular ACE activity. J Cardiovasc Pharmacol. 1997 May;29(5):684-91. DOI:10.1097/00005344-199705000-00018
[2] Carr RD, et al. Preferential biliary elimination of FPL 63547, a novel inhibitor of angiotensin-converting enzyme, in the rat. Br J Pharmacol. 1990 May;100(1):90-4. DOI:10.1111/j.1476-5381.1990.tb12057.x |
|
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
| Company Name: |
Leancare Ltd.
|
| Tel: |
+33 962096793 |
| Website: |
www.leancare.co.uk |
|